News | September 15, 2009

Tryton Celebrates 250th Implant of its Side Branch Stent System

September 15, 2009 – Tryton Medical Inc. said today its Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at bifurcations in patients with heart disease.

“Bifurcation lesions have presented a challenge for cardiologists since the earliest days of angioplasty,” said professor David Foley of Beaumont Hospital in Dublin, Ireland (formerly the cardiac catheterization lab director at Thoraxcentre, Rotterdam). “Current approaches to treating these cases entail adaptation of available stents, leading to complexity and increased risk of periprocedural complications and late restenosis. The Tryton Side Branch Stent offers a straightforward approach to first securing the side branch, while enabling trouble-free stenting of the main vessel using either a drug eluting or bare metal stent. Over the past two months, I have subjected the Tryton Stent to robust challenges in complex bifurcations and am happy to state that it has become an important tool for treating my patients with bifurcation lesions.”

Tryton Medical will exhibit the Tryton Side Branch Stent System in booth 630 at this year’s Transcatheter Cardiovascular Therapeutics (TCT) Conference Sept. 21-25, in San Francisco.

Tryton’s highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery. The stent received CE mark approval in Europe, but is not approved in the United States.

For more information: www.trytonmedical.com

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init